Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Friday, 1 September 2017, 10:06 HKT/SGT
Share:
    

Source: Eisai
Eisai to Present Abstracts on Oncology Products and Pipeline at ESMO 2017 Congress Three Abstracts on Lenvima (Lenvatinib) to be Presented in Oral Session

TOKYO, Sept 1, 2017 - (JCN Newswire) - Eisai Co., Ltd. announced today that a series of abstracts highlighting updates regarding its in-house discovered Lenvima/Kisplyx (lenvatinib mesylate, "lenvatinib", selective inhibitor of receptor tyrosine kinases with a novel binding mode), Halaven (eribulin mesylate, "eribulin", halichondrin class microtubule dynamics inhibitor), and E7046 (prostaglandin E2 receptor EP4 inhibitor) will be presented during the European Society for Medical Oncology (ESMO) 2017 Congress , taking place in Madrid, Spain, from September 8 to 12, 2017.

At the ESMO 2017 Congress, there will be an oral presentation on the results of a health-related Quality of Life analysis of patients from a Phase III clinical trial (REFLECT/Study 304) of lenvatinib versus sorafenib for unresectable hepatocellular carcinoma, and a separate oral presentation on the results of an analysis of biomarkers from the same study. In addition, there will be an oral presentation on the results of the metastatic renal cell carcinoma cohort from a Phase Ib/II clinical trial (Study 111) of lenvatinib in combination with anti-PD-1 antibody pembrolizumab.

There are six poster presentations scheduled, including presentations on the results of a primary analysis of a Phase II clinical trial of lenvatinib in biliary tract cancer, and the results of a Phase I clinical trial of E7046.

Eisai positions oncology as a key therapeutic area, and is aiming to discover revolutionary new medicines with the potential to cure cancer. Eisai will continue to create innovation in the development of new drugs based on cutting-edge cancer research, as it seeks to contribute further to addressing the diverse needs of, and increasing the benefits provided to, patients with cancer, their families, and healthcare providers.


About Eisai

Eisai Co., Ltd. (TSE:4523; ADR:ESALY) is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Eisai focuses its efforts in three therapeutic areas: integrative neuroscience, including neurology and psychiatric medicines; integrative oncology, which encompasses oncotherapy and supportive-care treatments; and vascular/immunological reaction. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide healthcare system. For more information about Eisai Co., Ltd., please visit www.eisai.com.

Contact:
Public Relations Department,
Eisai Co., Ltd.
+81-3-3817-5120


Sept 1, 2017 10:06 HKT/SGT
Source: Eisai

Eisai (TSE: 4523)

Topic: Press release summary
Sectors: BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2018 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Eisai
July 11, 2018 15:32 HKT/SGT
Eisai: Oral Antifungal Agent Nailin Capsules 100mg to be Launched in Japan
July 10, 2018 10:14 HKT/SGT
Eisai: Oral Presentation on Phase II Clinical Study Results of BAN2401 to be Presented at Alzheimer's Association International Conference (AAIC) 2018
July 9, 2018 14:07 HKT/SGT
Eisai: Results from Two Phase 3 Clinical Trials of Chronic Constipation Treatment "GOOFICE 5mg Tablet" Published in The Lancet Gastroenterology & Hepatology
July 6, 2018 09:31 HKT/SGT
Eisai and Biogen Announce Positive Topline Results of the Final Analysis for BAN2401 At 18 Months
July 4, 2018 17:18 HKT/SGT
Eisai Listed for 17th Consecutive Year in FTSE4GOOD Index Series
July 2, 2018 15:36 HKT/SGT
Eisai to Give Oral Presentation on Results of Phase III Head-to-Head Clinical Study of Lemborexant in Insomnia Disorder
June 22, 2018 10:58 HKT/SGT
Eisai Selected for Membership in MSCI Japan Empowering Women Index (WIN)
June 21, 2018 09:51 HKT/SGT
AbbVie and Eisai Announce the Launch of HUMIRA for Subcutaneous Injection 20 mg Syringe 0.2 mL
June 14, 2018 09:11 HKT/SGT
Eisai: Industry-Academia-Government Joint Development Agreement Concerning Nucleic Acid Drug Discovery Research
June 13, 2018 11:53 HKT/SGT
Eisai to Establish New Research Facility "Eisai Center for Genetics Guided Dementia Discovery" in Cambridge, Massachusetts, USA
More news >>
 News Alerts
Copyright © 2018 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 10 8405 3688 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 6721 7212

Connect With us: